204 related articles for article (PubMed ID: 36825684)
1. Tumor-derived insulin-like growth factor-binding protein-1 contributes to resistance of hepatocellular carcinoma to tyrosine kinase inhibitors.
Suzuki H; Iwamoto H; Seki T; Nakamura T; Masuda A; Sakaue T; Tanaka T; Imamura Y; Niizeki T; Nakano M; Shimose S; Shirono T; Noda Y; Kamachi N; Sakai M; Morita K; Nakayama M; Yoshizumi T; Kuromatsu R; Yano H; Cao Y; Koga H; Torimura T
Cancer Commun (Lond); 2023 Apr; 43(4):415-434. PubMed ID: 36825684
[TBL] [Abstract][Full Text] [Related]
2. Cancer-associated fibroblast-derived secreted phosphoprotein 1 contributes to resistance of hepatocellular carcinoma to sorafenib and lenvatinib.
Eun JW; Yoon JH; Ahn HR; Kim S; Kim YB; Lim SB; Park W; Kang TW; Baek GO; Yoon MG; Son JA; Weon JH; Kim SS; Cho HJ; Cheong JY
Cancer Commun (Lond); 2023 Apr; 43(4):455-479. PubMed ID: 36919193
[TBL] [Abstract][Full Text] [Related]
3. Insulin-like growth factor binding protein-1 inhibits cancer cell invasion and is associated with poor prognosis in hepatocellular carcinoma.
Dai B; Ruan B; Wu J; Wang J; Shang R; Sun W; Li X; Dou K; Wang D; Li Y
Int J Clin Exp Pathol; 2014; 7(9):5645-54. PubMed ID: 25337205
[TBL] [Abstract][Full Text] [Related]
4. Molecular Mechanisms of Resistance to Tyrosine Kinase Inhibitors Associated with Hepatocellular Carcinoma.
Tian Y; Lei Y; Fu Y; Sun H; Wang J; Xia F
Curr Cancer Drug Targets; 2022; 22(6):454-462. PubMed ID: 35362393
[TBL] [Abstract][Full Text] [Related]
5. Insulin-like growth factor binding protein-1 induces decidualization of human endometrial stromal cells via alpha5beta1 integrin.
Matsumoto H; Sakai K; Iwashita M
Mol Hum Reprod; 2008 Aug; 14(8):485-9. PubMed ID: 18583428
[TBL] [Abstract][Full Text] [Related]
6. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
7. Insulin-like growth factor-binding protein-3 inhibits IGF-1-induced proliferation of human hepatocellular carcinoma cells by controlling bFGF and PDGF autocrine/paracrine loops.
Ma Y; Han CC; Li Y; Wang Y; Wei W
Biochem Biophys Res Commun; 2016 Sep; 478(2):964-9. PubMed ID: 27521890
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia and hepatocellular carcinoma: The therapeutic target for hepatocellular carcinoma.
Wu XZ; Xie GR; Chen D
J Gastroenterol Hepatol; 2007 Aug; 22(8):1178-82. PubMed ID: 17559361
[TBL] [Abstract][Full Text] [Related]
9. Insulin-like growth factor-binding protein 1 stimulates human trophoblast migration by signaling through alpha 5 beta 1 integrin via mitogen-activated protein Kinase pathway.
Gleeson LM; Chakraborty C; McKinnon T; Lala PK
J Clin Endocrinol Metab; 2001 Jun; 86(6):2484-93. PubMed ID: 11397844
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis B Virus Small Envelope Protein Promotes Hepatocellular Carcinoma Angiogenesis via Endoplasmic Reticulum Stress Signaling To Upregulate the Expression of Vascular Endothelial Growth Factor A.
Wu SX; Ye SS; Hong YX; Chen Y; Wang B; Lin XJ; Lin X
J Virol; 2022 Feb; 96(4):e0197521. PubMed ID: 34910612
[TBL] [Abstract][Full Text] [Related]
11. Role of IGF-binding protein 3 in the resistance of EGFR mutant lung cancer cells to EGFR-tyrosine kinase inhibitors.
Choi YJ; Park GM; Rho JK; Kim SY; So GS; Kim HR; Choi CM; Lee JC
PLoS One; 2013; 8(12):e81393. PubMed ID: 24339922
[TBL] [Abstract][Full Text] [Related]
12. Caspase-3-Induced Activation of SREBP2 Drives Drug Resistance via Promotion of Cholesterol Biosynthesis in Hepatocellular Carcinoma.
Mok EHK; Leung CON; Zhou L; Lei MML; Leung HW; Tong M; Wong TL; Lau EYT; Ng IOL; Ding J; Yun JP; Yu J; Zhu HL; Lin CH; Lindholm D; Leung KS; Cybulski JD; Baker DM; Ma S; Lee TKW
Cancer Res; 2022 Sep; 82(17):3102-3115. PubMed ID: 35767704
[TBL] [Abstract][Full Text] [Related]
13. High expression of insulin-like growth factor binding protein-3 is correlated with lower portal invasion and better prognosis in human hepatocellular carcinoma.
Aishima S; Basaki Y; Oda Y; Kuroda Y; Nishihara Y; Taguchi K; Taketomi A; Maehara Y; Hosoi F; Maruyama Y; Fotovati A; Oie S; Ono M; Ueno T; Sata M; Yano H; Kojiro M; Kuwano M; Tsuneyoshi M
Cancer Sci; 2006 Nov; 97(11):1182-90. PubMed ID: 16965600
[TBL] [Abstract][Full Text] [Related]
14. Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma.
Chen Y; Hu H; Yuan X; Fan X; Zhang C
Front Immunol; 2022; 13():896752. PubMed ID: 35757756
[TBL] [Abstract][Full Text] [Related]
15. Integrin-mediated action of insulin-like growth factor binding protein-2 in tumor cells.
Schütt BS; Langkamp M; Rauschnabel U; Ranke MB; Elmlinger MW
J Mol Endocrinol; 2004 Jun; 32(3):859-68. PubMed ID: 15171717
[TBL] [Abstract][Full Text] [Related]
16. A possible role for insulin-like growth factor-binding protein-3 autocrine/paracrine loops in controlling hepatocellular carcinoma cell proliferation.
Huynh H; Chow PK; Ooi LL; Soo KC
Cell Growth Differ; 2002 Mar; 13(3):115-22. PubMed ID: 11959812
[TBL] [Abstract][Full Text] [Related]
17. ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma.
Myojin Y; Kodama T; Maesaka K; Motooka D; Sato Y; Tanaka S; Abe Y; Ohkawa K; Mita E; Hayashi Y; Hikita H; Sakamori R; Tatsumi T; Taguchi A; Eguchi H; Takehara T
Clin Cancer Res; 2021 Feb; 27(4):1150-1161. PubMed ID: 33288659
[TBL] [Abstract][Full Text] [Related]
18. Pilot study of elevated levels of insulin-like growth factor-binding protein-2 as indicators of hepatocellular carcinoma.
Ranke MB; Maier KP; Schweizer R; Stadler B; Schleicher S; Elmlinger MW; Flehmig B
Horm Res; 2003; 60(4):174-80. PubMed ID: 14530605
[TBL] [Abstract][Full Text] [Related]
19. Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma.
Toh TB; Lim JJ; Hooi L; Rashid MBMA; Chow EK
J Hepatol; 2020 Jan; 72(1):104-118. PubMed ID: 31541681
[TBL] [Abstract][Full Text] [Related]
20. Co-Localization of Insulin-Like Growth Factor Binding Protein-1, Casein Kinase-2β, and Mechanistic Target of Rapamycin in Human Hepatocellular Carcinoma Cells as Demonstrated by Dual Immunofluorescence and in Situ Proximity Ligation Assay.
Singal SS; Nygard K; Dhruv MR; Biggar K; Shehab MA; Li SS; Jansson T; Gupta MB
Am J Pathol; 2018 Jan; 188(1):111-124. PubMed ID: 29037858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
